A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris

Dova Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Acne Vulgaris

Treatments: Drug: Clindamycin; Drug: IDP-110; Drug: Vehicle; Drug: Benzoyl peroxide

Study type: Interventional

Funder types: Industry

Identifiers

NCT00664248

DPSI-06-22-2006-012

Details and patient eligibility

About

The purpose of this study is to assess the effectiveness of IDP-110 in treating patients with acne vulgaris.

Enrollment: 1,414 patients

Sex: All

Ages: 12 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Presence of inflammatory and non-inflammatory lesions

Exclusion criteria

• Dermatological conditions of the face other than acne that could interfere with clinical evaluations
• Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

1,414 participants in 4 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: IDP-110

2

Active Comparator group

Treatment:

Drug: Clindamycin

3

Active Comparator group

Treatment:

Drug: Benzoyl peroxide

4

Placebo Comparator group

Treatment:

Drug: Vehicle